Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells

被引:25
作者
Dezfouli, S
Bakke, A
Huang, J
Wynshaw-Boris, A
Hurlin, PJ
机构
[1] Shriners Hosp Children, Portland, OR 97239 USA
[2] Oregon Hlth Sci Univ, Dept Cell & Dev Biol, Portland, OR 97201 USA
[3] Oregon Hlth Sci Univ, Dept Pathol, Portland, OR 97201 USA
[4] Univ Calif San Diego, Sch Med, Ctr Comprehens Canc, Dept Pediat, San Diego, CA 92103 USA
[5] Univ Calif San Diego, Sch Med, Ctr Comprehens Canc, Dept Med, San Diego, CA 92103 USA
关键词
D O I
10.1128/MCB.26.6.2080-2092.2006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mnt is a Max-interacting protein that can antagonize the activities of Myc oncoproteins in cultured cells. Mnt null mice die soon after birth, but conditional deletion of Mnt in breast epithelium leads to tumor formation. These and related data suggest that Mnt functions as a tumor suppressor. Here we show that conditional deletion of Mnt in T cells leads to tumor formation but also causes inflammatory disease. Deletion of Mnt caused increased apoptosis of thymic T cells and interfered with T-cell development yet led to spleen, liver, and lymph node enlargement. The proportion of T cells in the spleen and lymph nodes was reduced, and the numbers of cells in non-T-cell immune cell populations were elevated. The disruption of immune homeostasis is linked to a strong skewing toward production of T-helper 1 (Th1) cytokines and enhanced proliferation of activated Mnt-deticient CD4(+) T cells. Consistent with Th1 polarization in vivo, extensive intestinal inflammation and liver necrosis developed. Finally, most mice lacking Mnt in T cells ultimately succumbed to T-cell lymphoma. These results strengthen the argument that Mnt functions as a tumor suppressor and reveal a critical and surprising role for Mnt in the regulation of T-cell development and in T-cell-dependent immune homeostasis.
引用
收藏
页码:2080 / 2092
页数:13
相关论文
共 57 条
[1]   Transcriptional regulation and transformation by MYC proteins [J].
Adhikary, S ;
Eilers, M .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2005, 6 (08) :635-645
[2]  
BLYTH K, 1995, ONCOGENE, V10, P1717
[3]  
BroussardDiehl C, 1996, J IMMUNOL, V156, P3141
[4]   Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway [J].
Buckley, AF ;
Kuo, CT ;
Leiden, JM .
NATURE IMMUNOLOGY, 2001, 2 (08) :698-704
[5]   Apparent bypass of negative selection in CD8(+) tumours in CD2-myc transgenic mice [J].
Cameron, ER ;
Campbell, M ;
Blyth, K ;
Argyle, SA ;
Keanie, L ;
Neil, JC ;
Onions, DE .
BRITISH JOURNAL OF CANCER, 1996, 73 (01) :13-17
[6]   Fas-independent apoptosis in T-cell tumours induced by the CD2-myc transgene [J].
Cameron, ER ;
Morton, J ;
Johnston, CJ ;
Irvine, J ;
Bell, M ;
Onions, DE ;
Neil, JC ;
Campbell, M ;
Blyth, K .
CELL DEATH AND DIFFERENTIATION, 2000, 7 (01) :80-88
[7]   The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation [J].
Cole, MD ;
McMahon, SB .
ONCOGENE, 1999, 18 (19) :2916-2924
[8]   Cell fate decision: T-helper 1 and 2 subsets in immune responses [J].
Dong, C ;
Flavell, RA .
ARTHRITIS RESEARCH, 2000, 2 (03) :179-188
[9]   Defining the specific physiological requirements for c-Myc in T cell development [J].
Douglas, NC ;
Jacobs, H ;
Bothwell, ALM ;
Hayday, AC .
NATURE IMMUNOLOGY, 2001, 2 (04) :307-315
[10]  
ELSON A, 1995, ONCOGENE, V11, P181